Archive by Author

Indalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965

indalojpg

Oral integrin antagonist inhibits multiple processes of pathologic fibrosisIndalo to present at NASH Summit in Boston, MA, on April 24th Cambridge, MA, April 18, 2019 – Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF), today announced the […]

Comments Off on Indalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965 Continue Reading →

Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion

Catalent_Biologics-1080x675

Will provide new expertise and capabilities in one of the fastest-growing areas of healthcare, positioning Catalent for accelerated long-term growth SOMERSET, N.J. and BALTIMORE, M.D. – April 15, 2019 – Catalent, Inc. (NYSE: CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, and Paragon Bioservices, […]

Comments Off on Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion Continue Reading →

MaxCyte® Launches ExPERT™ Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies

MAXCYTE-New-Logo-2016-LARGE

MaxCyte, the global clinical-stage cell-based medicines and life sciences company, announced today the launch of the new ExPERT™ technology platform. This family of instruments – the ATx, STx and GTx – represents the next generation of the industry’s leading, clinically validated Flow Electroporation® technology for complex cellular engineering. With these additions to the product portfolio, […]

Comments Off on MaxCyte® Launches ExPERT™ Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies Continue Reading →

Paragon Bioservices Appoints New CTSO, Bolsters Leadership Ranks to Support Late-Stage Clinical and Commercial Biopharmaceutical Manufacturing

Paragon

Appointments and Promotions Continue to Position Paragon as Industry-Leading Gene Therapy and Vaccine CDMO Paragon Bioservices, the leading private equity-backed, biologics contract development and manufacturing organization (CDMO) announced today the appointment of Thomas VanCott, Ph.D., as Chief Technology and Strategy Officer (CTSO), along with several key promotions and new hires. “We are thrilled to welcome Tom […]

Comments Off on Paragon Bioservices Appoints New CTSO, Bolsters Leadership Ranks to Support Late-Stage Clinical and Commercial Biopharmaceutical Manufacturing Continue Reading →

AURP Announces Brian Darmody as New CEO and Launches ‘AURP HQ2’ in Washington, DC Area

B Darmody

The Association of University Research Park, a professional association of university-related research and science parks, announced the appointment of Brian Darmody, Associate Vice President of Corporate Engagement at the University of Maryland (UMD), as its new Chief Executive Officer (CEO). Additionally, the association has opened a new office at the UMD Discovery District in the Washington, DC area, to […]

Comments Off on AURP Announces Brian Darmody as New CEO and Launches ‘AURP HQ2’ in Washington, DC Area Continue Reading →

Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO

Robert-Jacks_4268Cc-Web_for wire distro

Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF), today announced that Robert Jacks has been appointed President & CEO. Mr. Jacks brings to Indalo 18 years of experience in biopharmaceutical product development, corporate strategy, business development, […]

Comments Off on Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President & CEO Continue Reading →

PressComm PR Client Rachel King, CoFounder and CEO, GlycoMimetics Inc. Featured on PharmaVOICE Podcast

King-Rachel-PVcom-FeaturedImage630x315-560x315

Rachel King has charted a unique career — from consultant to VC to startup to now CEO — and is leading a pioneering company in the use of glycobiology technology. Click here to listen to the podcast via Pharmavoice.com”

Comments Off on PressComm PR Client Rachel King, CoFounder and CEO, GlycoMimetics Inc. Featured on PharmaVOICE Podcast Continue Reading →

Popper and Company Adds Diagnostic Industry Leaders as Senior Advisors

popper

Popper and Co., a strategy consulting and transaction advisory firm guiding medical technology and life sciences companies working on the leading-edge of diagnostics and patient management, announced today the addition of Vincent Linder, PhD and Gene Vivino to its growing team of industry and clinical senior advisors. Both Dr. Linder and Mr. Vivino provide strong industry knowledge and extensive operating […]

Comments Off on Popper and Company Adds Diagnostic Industry Leaders as Senior Advisors Continue Reading →

Welldoc Achieves Significant Digital Health Milestone by Securing Its 10th Patent for Its BlueStar Digital Therapeutic

bluestar_jpg

Welldoc®, a leading digital health company, announced today that it has secured a technology patent (based on U.S. Patent Application No. 15/923,010) from the United States Patent and Trademark Office for the Software Engine Technology that powers its BlueStar® digital therapeutic. “The awarding of this tenth technology patent to Welldoc is a validation of our […]

Comments Off on Welldoc Achieves Significant Digital Health Milestone by Securing Its 10th Patent for Its BlueStar Digital Therapeutic Continue Reading →

WBJ Viewpoint Piece from BHI’s Rich Bendis and UMD’s Brian Darmody on Boosting Federal Tech Transfer

img_KAP_BioInnovations_Rich_001--Edit

While Maryland boasts world-class universities and many private sector firms, the major reason it ranks No. 1 in the country in per capita research spending is the presence of 74 federal research laboratories, such as the National Institutes of Health. Our federal laboratories host supremely talented researchers, including Nobel Prize winners, and house some of […]

Comments Off on WBJ Viewpoint Piece from BHI’s Rich Bendis and UMD’s Brian Darmody on Boosting Federal Tech Transfer Continue Reading →